BDBM72349 1-[[2-(2-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl]-5-phenyl-3H-1,4-benzodiazepin-2-one::1-[[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]methyl]-5-phenyl-3H-1,4-benzodiazepin-2-one::1-[[2-(2-chlorophenyl)-5-methyl-oxazol-4-yl]methyl]-5-phenyl-3H-1,4-benzodiazepin-2-one::1-{[2-(2-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methyl}-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one::MLS000586889::SMR000208819::cid_15945564

SMILES O=C1c2cc(F)c(C(F)(F)F)cc2N2CN1c1ccc(=O)[nH]c1CCNCc1cc(Cl)ccc12

InChI Key InChIKey=WDDMDYBPCMTPSP-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 72349   

TargetSodium channel protein type 10 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandChemical structure of BindingDB Monomer ID 72349BDBM72349(8-Chloro-2-fluoro-3-(trifluoromethyl)-10,11,12,13-...)
Affinity DataIC50: 6.31nMAssay Description:Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, MG132, NIH3T3, Luminescence Assay Overview: Modified NIH3T3, transformed to express firefly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2026
Entry Details
US Patent